- Home
- GDO vs ARMP Comparison
GDO vs ARMP Comparison
Compare GDO & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDO | ARMP |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.8M | 125.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GDO | ARMP |
|---|---|---|
| Price | $11.65 | $6.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 39.4K | 29.5K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 9.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.21 | $0.90 |
| 52 Week High | $13.04 | $16.34 |
Technical Indicators
Market Signals| Indicator | GDO | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 57.38 |
| Support Level | $11.62 | $5.87 |
| Resistance Level | $11.88 | $6.60 |
| Average True Range (ATR) | 0.12 | 0.45 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 3.23 | 92.86 |
Price Performance
Historical ComparisonAbout GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.